Immuno-Oncology | Specialty

Daily Aspirin for Colorectal Cancer Prevention

July 16th 2015

Impact of the SIRFLOX Study on CRC Management

July 16th 2015

Role of Surgery in Metastatic Colorectal Cancer

July 16th 2015

Broad Molecular Profiling in Colorectal Cancer

July 16th 2015

Genetic Testing in Colorectal Cancer

July 16th 2015

PD-1 Blockade Effective in Mismatch Repair-Deficient CRC

July 15th 2015

James J. Lee, MD, PhD, discusses research into mismatch repair deficiency as a biomarker for PD-1 inhibition in colorectal cancer.

Dr. Bang on Pembrolizumab for Advanced Gastric Cancer

July 15th 2015

Yung-Jue Bang, MD, PhD, discusses pembrolizumab for the treatment of advanced gastric cancer. Pembrolizumab was investigated as part of the KEYNOTE-012 study, which looked at the checkpoint inhibitor across several solid tumors.

Atezolizumab Achieves Primary Endpoint in Pivotal Phase II Bladder Cancer Study

July 13th 2015

Second-line treatment with atezolizumab (MPDL3280A) has met the primary endpoint of a pivotal phase II study by effectively shrinking tumors in patients with locally advanced or metastatic urothelial bladder cancer.

Adding Atezolizumab to Chemotherapy Shows Promise in NSCLC

July 10th 2015

Stephen Liu, MD, discusses the results and purpose of the uniquely designed trial examining atezolizumab in combination with platinum-based doublet chemotherapy in treatment-naïve patients with advanced non–small cell lung cancer.

How a Rebellious Scientist Helped Launch the Modern Age of Immunotherapy

July 5th 2015

James P. Allison, PhD, was honored in the Scientific Advances category with a 2014 Giants of Cancer Care® award, a program that the Intellisphere® Oncology Specialty Group launched to honor leaders in the field.

New Agents Show Promise in Gastric Cancer

July 3rd 2015

Josep Tabernero, MD, PhD, summarized novel agents that are currently under exploration for patients with gastric cancer.

Immunotherapy in Melanoma: What Does the Future Hold?

June 25th 2015

Howard L. Kaufman, MD, discusses the rapidly advancing immunotherapy armamentarium in melanoma.

Interpreting PD-L1 Status Among Key Melanoma Topics at ASCO

June 25th 2015

OncLive sat down with Jason J. Luke, MD, discusses the key areas in the treatment of melanoma discussed at the 2015 ASCO Annual Meeting included selecting appropriate immunotherapy regimens based on PD-L1 status and improving surgical practices.

Future Immunotherapies for Hematologic Malignancies

June 24th 2015

PD-1 Inhibition in Hodgkin's Lymphoma

June 24th 2015

Treatment Advancements in Lymphoma

June 24th 2015

Daratumumab, Vaccines in Multiple Myeloma

June 24th 2015

Elotuzumab in Relapsed/Refractory Multiple Myeloma

June 24th 2015

Measuring Response to Novel Therapies in ALL

June 24th 2015

Blinatumomab in Philadelphia Chromosome-Negative ALL

June 24th 2015